Health ❯Healthcare ❯Clinical Trials

Drug Development

Combination Therapy Alzheimer's Treatments Targeted Therapy Eli Lilly Phase 2 Trials Oral Medications Azelaprag Patient Outcomes Lenacapavir Phase III Trials

Monthly Oral PrEP Candidate MK-8527 Shows Early Promise in Merck Study

The PLOS Biology paper outlines preclinical results with early safety signals that support a once-monthly dosing strategy.

Kidney Organoids Reveal NFκB‑Linked AAV2 Toxicity, With Bardoxolone Methyl Mitigating Damage

Intratumoral Fc-Optimized CD40 Antibody Achieves Systemic Remissions in Phase 1 Study

TAR-200 Clears Tumors in 82% of High-Risk Bladder Cancer Patients, Advances to FDA Priority Review

Blocking DKK1 Reprograms Neutrophils and Revives Immunotherapy in Bone Metastases

Engineered Antibody Transport Vehicle Boosts Alzheimer’s Antibody Delivery to Mouse Brain

Johns Hopkins Grows Vascularized Multi-Region Brain Organoid

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

YCT-529 Advances to Extended Human Trials After Clearing Initial Safety Test

Experimental ODN-Derived Drug Curbs Appetite Without Nausea

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market

Weekly Parkinson’s Injection Secures Patent After Successful Lab Trials

MLi-2 Kinase Inhibitor Fully Restores Neuronal Cilia and Promotes Recovery in a Parkinson’s Mouse Model

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial

Dual Enzyme Inhibitors Convert Neuroblastoma Tumors into Healthy Neurons in Mice

Chemotherapy-Free Regimen Shows 94% Progression-Free Survival in CLL Trial

FDA Approves 95% Sensitive Blood Test for Alzheimer’s

Zigakibart sustains proteinuria remission and stabilizes kidney function over 100-week IgA nephropathy trial

Alzheimer’s Drug Trials Surge 11% in 2025 as NICE Reviews Lecanemab and Donanemab

New Triple-Drug Regimen Boosts Survival in PIK3CA-Mutant HR+ HER2- Breast Cancer